Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer

Drug Delivery and Translational Research

Volumn 1, Issue 6, 2011, Pages 420-428

  Li, Feng ^a   Danquah, Michael ^a   Singh, Saurabh ^a   Wu, Hao ^a   Mahato, Ram I ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Lapatinib; Lipopolymer; Multidrug resistance; Paclitaxel; Prostate cancer

Indexed keywords

GLYCOPROTEIN P; LAPATINIB; LAURYL ALCOHOL; MACROGOL; PACLITAXEL; POLY(ETHYLENE GLYCOL) BLOCK POLY(2 METHYL 2 CARBOXYLPROPYLENE CARBONATE GRAFT DODECANOL); PROPYLENE CARBONATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HYDROPHOBICITY; MALE; MITOSIS; MONOTHERAPY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VOLUME;

EID: 84862984190     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-011-0042-2     Document Type: Article

References (30)

1. Theyer G, Schirmbock M, Thalhammer T, Sherwood ER, Baumgartner G, Hamilton G. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urol. 1993; 150(5 Pt 1): 1544-7.
2. van Brussel JP, Mickisch GH. Multidrug resistance in prostate cancer. Onkologie. 2003; 26(2): 175-81. doi: 10. 1159/000071510.
3. Sanchez C, Mendoza P, Contreras HR, Vergara J, McCubrey JA, Huidobro C, et al. Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate. 2009; 69(13): 1448-59. doi: 10. 1002/pros. 20991.
4. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3): 219-34. doi: 10. 1038/nrd1984.
5. Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev. 2011; 63(8): 623-39. doi: 10. 1016/j. addr. 2010. 11. 005.
6. Li F, Lu Y, Li W, Miller DD, Mahato RI. Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100. J Control Release. 2010; 143(1): 151-8. doi: 10. 1016/j. jconrel. 2009. 12. 028.
7. Rahman A, Husain SR, Siddiqui J, Verma M, Agresti M, Center M, et al. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J Natl Cancer Inst. 1992; 84(24): 1909-15.
8. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 2009; 69(9): 3918-26. doi: 10. 1158/0008-5472. CAN-08-2747.
9. Minko T, Kopeckova P, Pozharov V, Kopecek J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release. 1998; 54(2): 223-33.
10. Carcaboso AM, Elmeliegy MA, Shen J, Juel SJ, Zhang ZM, Calabrese C, et al. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Res. 2010; 70(11): 4499-508. doi: 10. 1158/0008-5472. CAN-09-4264.
11. Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008; 30(8): 1426-47. doi: 10. 1016/j. clinthera. 2008. 08. 008.
12. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 2008; 68(19): 7905-14. doi: 10. 1158/0008-5472. CAN-08-0499.
13. Kuang YH, Shen T, Chen X, Sodani K, Hopper-Borge E, Tiwari AK, et al. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol. 2010; 79(2): 154-61. doi: 10. 1016/j. bcp. 2009. 08. 021.
14. Collins DM, Crown J, O'Donovan N, Devery A, O'Sullivan F, O'Driscoll L, et al. Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. Investig New Drugs. 2010; 28(4): 433-44. doi: 10. 1007/s10637-009-9266-0.
15. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008; 100(9): 672-9. doi: 10. 1093/jnci/djn123.
16. Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW, et al. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res. 2005; 65(8): 3404-9. doi: 10. 1158/0008-5472. CAN-04-4292.
17. Shaw G, Prowse DM. Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling. Cancer Cell Int. 2008; 8: 3. doi: 10. 1186/1475-2867-8-3.
18. Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, et al. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol. 2010; 33(6): 609-13. doi: 10. 1097/COC. 0b013e3181beac33.
19. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008; 26(34): 5544-52. doi: 10. 1200/JCO. 2008. 16. 2578.
20. Yamamoto T, Yokoyama M, Opanasopit P, Hayama A, Kawano K, Maitani Y. What are determining factors for stable drug incorporation into polymeric micelle carriers? Consideration on physical and chemical characters of the micelle inner core. J Control Release. 2007; 123(1): 11-8.
21. Leung SY, Jackson J, Miyake H, Burt H, Gleave ME. Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. Prostate. 2000; 44(2): 156-63.
22. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2): 271-84.
23. Greish K, Nagamitsu A, Fang J, Maeda H. Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity. Bioconjugate Chem. 2005; 16(1): 230-6.
24. Li F, Danquah M, Mahato RI. Synthesis and characterization of amphiphilic lipopolymers for micellar drug delivery. Biomacromolecules. 2010; 11(10): 2610-20. doi: 10. 1021/bm100561v.
25. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000; 88(11): 2619-28. doi: 10. 1002/1097-0142(20000601)88: 11.
26. Dunne G, Breen L, Collins DM, Roche S, Clynes M, Connor R. Modulation of P-gp expression by lapatinib. Investig New Drugs. 2010. doi: 10. 1007/s10637-010-9482-7.
27. Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochem Pharmacol. 2006; 72(8): 941-8. doi: 10. 1016/j. bcp. 2006. 07. 022.
28. Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res. 2001; 61(2): 739-48.
29. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996; 2(11): 1843-9.
30. Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol. 2007; 14(2): 942-53. doi: 10. 1245/s10434-006-9227-1.